Tagged: signal-peptides
2 results
Avenue Biosciences
Avenue Biosciences is a transatlantic biotech building the first platform to measure and modulate the cellular secretory pathway at scale. Spun out of the University of Helsinki and headquartered between Helsinki and Palo Alto, the company pairs high-throughput chemistry with machine learning to design signal peptides and boost yields of therapeutic proteins - biologics, biosimilars, and mRNA-encoded medicines - so that production bottlenecks stop limiting which therapies reach patients.
Tero-Pekka Alastalo
Tero-Pekka Alastalo is a Finnish-born physician-scientist turned serial entrepreneur who trained as a pediatric cardiologist, completed his postdoctoral work at Stanford University School of Medicine, and has spent the last 15 years building life science companies in Silicon Valley. He co-founded Blueprint Genetics in 2012 - a clinical genetic testing company later acquired by Quest Diagnostics in 2020 - before launching Avenue Biosciences in 2023, a transatlantic AI-powered protein engineering company that uses signal peptide libraries and machine learning to unlock the secretory pathway and dramatically boost therapeutic protein yields. Based in Menlo Park, California, Alastalo is turning a fundamental cellular mechanism overlooked by the industry into a platform that could accelerate every class of next-generation biologic.